DRDO's Anti-Covid Drug 2-DG Effective Against All Covid-19 S
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A new study has claimed that 2-DG, the drug against Covid-19 developed by the Defence Research and Development Organisation (DRDO), is effective against all variants of Covid-19 and even reduces the multiplicity of the SARS-CoV-2 virus. The preliminary study also showed that DRDO's anti-Covid drug alleviates cells from infection-induced cytopathic effect (CPE) and cell death.

While releasing the first batch of DRDO's anti-Covid drug, the central government claimed that the drug has the potential to reduce a patient's average recovery time by two and a half days and oxygen demand by up to 40%. It was provided authorisation for emergency use by the Drugs Controller General of India (DCGI) on June 1 as an adjunct therapy for moderate to severe coronavirus patients.

DRDO's anti-Covid drug 2-DG was used in the study to aim and inhibit the "metabolic reprogramming" induced by Covid-19 infection in patients suffering from the disease. The results showed that the Covid 19 infection causes a high influx of glucose in the body and glycolysis in the cells, resulting in selective high accumulation of the fluorescent glucose/2-Dg analogue and 2-NBDG. This reduced virus multiplication and alleviated the cells from infection-induced cell death.

DRDO's anti-Covid drug 2-DG has been approved for use in the. The effect of the drug on patients with comorbidities such as uncontrolled diabetes, severe cardiac problems, and even renal impairment, ARDS, etc. has not been studied yet. DRDO advises that the 2-dg be prescribed as early into the treatment cycle of moderate to severe Covid-19 patients as possible, for a maximum duration of up to 10 days.

Dr. T●●●●z H●●●●●●i and 14 others like this6 shares